The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 959-963

  Fuchs, Ilka ^a   Vorsteher, N ^a   Buhler H ^b   Evers, K ^a   Sehouli, J ^a   Schaller, G ^c   Kummel S ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Breast Care Institute (BCI)   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cervical cancer; Fluorescence in situ hybridization; Gene amplification; HER family; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 34247127937     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pecorelli S, Pasinetti B, Angioli R, Favalli G and Odicino F: Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. Cancer Chemother Biol Response Modif 22: 515-544, 2005.
2. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
3. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M and Yarden Y: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467, 1996.
4. Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC and Yarden Y: Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16: 4938-4950, 1997.
5. Klijn JG, Berns PM, Schmitz PI and Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5323 patients. Endocr Rev 13: 3-17, 1992.
6. Janmaat ML and Giaccone G: Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8: 576-586,2003.
7. Allen LF, Lenehan PF, Eiseman IA, Elliott WL and Fry DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29: 11-21, 2002.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
9. Fuchs IB, Siemer I, Buehler H, Schmider A, Henrich W, Lichtenegger W, Schaller G and Kuemmel S: Epidermal growth factor receptor changes during breast cancer metastasis. Anticancer Res 26: 4397-4402, 2006.
10. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
11. Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, Vela-Chavez T, Candelaria M, Cetina L, Vidal S and Duenas-Gonzalez A: HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 4: 59-65, 2004.
12. Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T, Matsuura S and Hirohashi S: Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 73: 148-153, 1994.
13. Lee JS, Kim HS, Jung JJ, Lee MC and Park CS: Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol 85: 469-475, 2002.
14. Witton CJ, Reeves JR, Going JJ, Cooke TG and Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290-297, 2003.
15. Califano D, Losito S, Pisano C, Santelli G, Greggi S, Iodice F, DiVagno G, Silvestro G, Tambaro R, Formato R, Iaffaioli VR, Di Maio M and Pignata S: Significance of erb-B2 immunoreactivity in cervical cancer.Front Biosci 11: 2071-2076, 2006.
16. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J and Van de Vijver MJ: Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5: 577-586, 1999.
17. Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K and Tsujii H: Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer 13: 849-855, 2003.
18. Kim YT, Park SW and Kim JW: Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 87: 84-89, 2002.
19. Leung TW, Cheung AN, Cheng DK, Wong LC and Ngan HY: Expressions of c-erbB-2, epidermal growth factor receptor and panras proto-oncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. Oncol Rep 8: 1159-1164, 2001.
20. Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY and Wong LC: Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 22: 176-183, 2001.
21. Lee CM, Lee RJ, Hammond E, Tsodikov A, Dodson M, Zempolich K and Gaffney DK: Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 93: 209-214, 2004.
22. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL and Gaffney DK: Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 99: 415-421, 2005.
23. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T and Nexo E: Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 91: 2034-2041, 2004.
24. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T and Nexo E: The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer 94: 1703-1709, 2006.
25. Gullick WJ: c-erbB-4/HER4: friend or foe? J Pathol 200: 279-281, 2003.
26. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR and Cooke TG: Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 6: 246-251, 2004.
27. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B and Earp HS 3rd: Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21: 4265-4275, 2001.